89 related articles for article (PubMed ID: 9577579)
1. [Long-term prognosis of chronic hepatitis C--special reference to interferon therapy].
Arakawa Y
Nihon Naika Gakkai Zasshi; 1998 Mar; 87(3):480-5. PubMed ID: 9577579
[No Abstract] [Full Text] [Related]
2. [Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration].
Fukuda A
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):493-6. PubMed ID: 15359848
[No Abstract] [Full Text] [Related]
3. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
[TBL] [Abstract][Full Text] [Related]
5. [Alternative measures for patients with chronic hepatitis C unresponsive to interferon therapy].
Imazeki F
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):540-3. PubMed ID: 15359858
[No Abstract] [Full Text] [Related]
6. [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].
Nishiguchi S; Kubo S; Shiomi S
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):600-4. PubMed ID: 15359868
[No Abstract] [Full Text] [Related]
7. Summaries for patients. Does interferon-alpha prevent recurrence of malignant tumors in patients with hepatitis C - related liver cancer?
Ann Intern Med; 2001 May; 134(10):S-7. PubMed ID: 11357861
[No Abstract] [Full Text] [Related]
8. Prolonged therapy for hepatitis C with low-dose peginterferon.
Hoshida Y; Golub TR
N Engl J Med; 2009 Mar; 360(11):1152; author reply 1152-3. PubMed ID: 19283891
[No Abstract] [Full Text] [Related]
9. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: further evidence in decompensation cirrhosis.
Ji F; Zhang S; Deng H; Li Z
J Hepatol; 2013 Jun; 58(6):1262-4. PubMed ID: 23395693
[No Abstract] [Full Text] [Related]
11. [Efficacy of combined antiviral therapy with interferon alfa and ribavirin in chronic hepatitis C patients with extrahepatic manifestations].
Zarebska-Michaluk D; Lebensztejn DM; Kryczka W
Przegl Epidemiol; 2007; 61(3):551-8. PubMed ID: 18069393
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of chronic hepatitis C with IFN].
Matsushima T
Hokkaido Igaku Zasshi; 1993 Jul; 68(4):468-72. PubMed ID: 8393421
[No Abstract] [Full Text] [Related]
13. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
[TBL] [Abstract][Full Text] [Related]
14. [Chronic hepatitis C: what to do if the first treatment failed?].
Asselah T
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B50-9. PubMed ID: 12180309
[No Abstract] [Full Text] [Related]
15. Maintenance interferon for chronic hepatitis C: more issues than answers?
Everson GT
Hepatology; 2000 Aug; 32(2):436-8. PubMed ID: 10915756
[No Abstract] [Full Text] [Related]
16. [Clinical aspects of type-C cirrhosis of liver--diagnosis, clinical course, treatment and prognosis].
Yamada G
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):590-5. PubMed ID: 15359866
[No Abstract] [Full Text] [Related]
17. Short-term interferon therapy for chronic hepatitis C patients with low viral load.
Sato Y; Tokuue H; Kawamura N; Nezu-Yajima S; Nakajima H; Ishida H; Takahashi S
Hepatogastroenterology; 2004; 51(58):968-72. PubMed ID: 15239226
[TBL] [Abstract][Full Text] [Related]
18. 24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.
van Leeuwen DJ; Yee LJ; Langner RG
Am J Gastroenterol; 2002 Feb; 97(2):497-8. PubMed ID: 11866304
[No Abstract] [Full Text] [Related]
19. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.
Villa E; Grottola A; Buttafoco P; Colantoni A; Bagni A; Ferretti I; Cremonini C; Bertani H; Manenti F
Am J Gastroenterol; 2001 Oct; 96(10):2973-7. PubMed ID: 11693335
[TBL] [Abstract][Full Text] [Related]
20. Interferons in the management of viral hepatitis.
Zein NN
Cytokines Cell Mol Ther; 1998 Dec; 4(4):229-41. PubMed ID: 10068057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
